LMND Q1 2026 Earnings Narrowing Losses Beat Expectations as Underwriting Improves CATO Q4 2025 Earnings Loss of 055 per Share Amid Challenging Retail Environment SGMT Q1 2026 Earnings EPS Beat as Clinical Development Costs Tighten FMNB Q1 2026 Earnings Strong EPS Beat Drives Investor Attention Despite Slight Stock Dip Milestone Pharmaceuticals MIST Q1 2026 Earnings EPS Miss Deepens as ClinicalStage Biotech Navigates Development Path Velocity Financial Q1 2026 Earnings EPS Beat Fails to Boost Stock